Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2017 | Personalized dosing of pembrolizumab has the potential to save $0.8 billion per year

Dr Daniel A. Goldstein, MD, from the Davidoff Cancer Center, Israel, describes his investigation into the cost of pembrolizumab dosing in lung cancer patients. Pembrolizumab was developed by MSD and has shown to be effective in lung cancer patients; however, immunotherapeutic agents like pembrolizumab are very expensive. Dr Goldstein noticed that in clinical trials of pembrolizumab a variety of dosing schedules were incorporated; in fact, often lower doses did not result in decreased efficacy. Here, he tells us about his study, published during ASCO 2017 in JNCI (tinyurl.com/y9as9q76 ), which outlines how we could save approximately $0.8bn USD per year by personalising doses of pembrolizumab rather than using the fixed dosing regimen enforced by MSD.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.